http://www.takeda.com/ R&D News http://www.takeda.com/ http://www.takeda.com/favicon.ico icon http://www.takeda.com/press/article_35859.html H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today jointly announced the plans for the additional clinical phase III studies on Lu AA21004 and phase III studies on Lu AA24530 in patients with major depressive disorder (MDD). 2010-03-03T16:30:00+09:00 http://www.takeda.com/press/article_35851.html San Diego, CA – February, 22 and Osaka, Japan – February 23, 2010 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss. 2010-02-23T08:30:00+09:00 http://www.takeda.com/press/article_35844.html Osaka, Japan (Feb-18) Takeda Pharmaceutical Company Limited “Takeda” today announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc (Palo Alto, Calif) “Affymax” contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase 3 clinical program in Japan. 2010-02-18T15:00:00+09:00 http://www.takeda.com/press/article_35792.html Osaka, Japan and London, UK, February 1 - Takeda Pharmaceutical Company Limited (“Takeda”) and Takeda Pharmaceuticals Europe Limited (“TPEU”), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact® (mifamurtide)1, the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)2, is now commercially available in the European Union - via a paid named-patient programme in countries where it is not initially reimbursed. 2010-02-01T16:00:00+09:00 http://www.takeda.com/press/article_35785.html January 18, Osaka, Japan – Takeda Pharmaceutical Company Limited (“Takeda”) today announced it has received approval from the Japanese Ministry of Health, Labour and Welfare for Actos® OD tablets 15 and 30 (pioglitazone HCI; Actos OD tablets), for the treatment of type 2 diabetes. Takeda is the originator of Actos which helps reduce insulin resistance, which is one of the major causes of type 2 diabetes. In Japan, Actos tablets were approved and launched in 1999, and a New Drug Application for the new OD tablet formulation was submitted in September 2008. 2010-01-18T15:00:00+09:00